Clinical Trials & Research
Search Clinical Trials
Clinical Trials
New Search
| Title | Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety |
|---|---|
| Disease/Condition | Thyroid Cancer |
| Description | |
| Eligibility Criteria | Ages Eligible for Study: 18 Years and older (Adult, Senior) Genders Eligible for Study: Both Accepts Healthy Volunteers: No Click here for eligibility requirements |
| Principal Investigator | Missak Haigentz, MD |
| Contact Name | Karen Fehn |
| Phone | (718) 405-8446 |
| Contact Email | CPDMUtrialinfo@montefiore.org |
| Protocol Number | IRB# 15-06-381-01 |
| Inclusion/Notes | This information was obtained from ClinicalTrials.gov. |
| Status | Enrolling |
| Adult Clinical Trial | Yes |
| Pediatric Clinical Trial | No |
